Nutriband Inc. (NASDAQ: NTRB) 25% Preferred Stock Dividend FAQ

What is the main topic of the announcement?

The announcement is about Nutriband Inc. offering a 25% preferred stock dividend to its shareholders, with specific dates for eligibility and payment.

Why is this dividend significant?

This dividend is significant because it offers shareholders additional value through preferred shares, which can be converted to common shares upon FDA approval of Nutriband’s AVERSA Fentanyl product or yield annual cash dividends.

How does the preferred stock dividend work?

Shareholders of record by July 25, 2025, will receive one preferred share for every four common shares held, payable on August 5, 2025, with each preferred share convertible to one common share upon FDA approval of the AVERSA Fentanyl product.

Who is eligible for the preferred stock dividend?

Shareholders who hold Nutriband Inc. common shares as of the record date, July 25, 2025, are eligible for the dividend.

When will the dividend be paid?

The dividend will be paid on August 5, 2025, to shareholders of record as of July 25, 2025.

What are the implications of the preferred shares being convertible?

The convertibility feature means that preferred shares can be turned into common shares upon FDA approval of the AVERSA Fentanyl product, potentially increasing the shareholder’s stake in the company.

What happens to preferred shares that are not converted?

Unconverted preferred shares may be eligible for annual cash dividends from company profits, at the discretion of the board.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their official website at www.Nutriband.com or in the company’s newsroom at https://ibn.fm/NTRB.

How can I stay updated on Nutriband Inc. news?

To receive the latest news and updates, you can visit the company’s newsroom at https://ibn.fm/NTRB or sign up for SMS alerts from BioMedWire by texting “Biotech” to 888-902-4192 (U.S. Mobile Phones Only).